Metastatic Prostate Cancer

1. Disease Information

Overview / definition

Metastatic prostate cancer is prostate adenocarcinoma that has disseminated beyond the prostate and regional tissues to distant sites (AJCC M1 disease), most commonly bone and lymph nodes. Clinically, metastatic disease is often subclassified by response to androgen deprivation therapy (ADT) into: - Metastatic hormone-sensitive prostate cancer (mHSPC): metastatic disease that has not yet developed resistance to castration-level testosterone. - Metastatic castration-resistant prostate cancer (mCRPC): metastatic disease with progression despite ongoing ADT and castrate testosterone levels.

A recent review describes the mCRPC state as progression despite castrate testosterone levels (often defined as <50 ng/dL) and diagnosis by biochemical (rising PSA) and/or radiologic progression while on ADT (cicchetti2025therapeuticadvancesin pages 1-2).

Key identifiers (available in retrieved sources)

• ICD-10 (primary site): C61 (Prostate) (inferred as standard coding used in population registries summarized in CA Cancer J Clin; ICD-O site C61 used for incidence statistics) (kratzer2025prostatecancerstatistics pages 2-3).
• MeSH / OMIM / Orphanet / MONDO: Not available in retrieved sources in this run.

Synonyms / alternative names

• Metastatic prostate cancer (mPC)
• Metastatic hormone-sensitive prostate cancer (mHSPC); metastatic castration-sensitive prostate cancer (mCSPC)
• Metastatic castration-resistant prostate cancer (mCRPC)

Evidence sources

The evidence used here comes from aggregated disease-level resources (EAU guideline; CA Cancer J Clin population statistics), clinical trials and regulatory summaries, and real-world claims/registry studies, rather than single-patient EHR narratives (tilki2024eaueanmestroesurisupsiogguidelineson pages 1-3, kratzer2025prostatecancerstatistics pages 1-2, raval2025realworldevidenceof pages 1-2).

EAU 2024 guideline resource URL: https://doi.org/10.1016/j.eururo.2024.04.010 (published online 2024-08) (tilki2024eaueanmestroesurisupsiogguidelineson pages 1-3).

2. Etiology

Disease causal factors (mechanistic)

Metastatic progression and castration resistance are strongly driven by androgen receptor (AR) biology and clonal evolution under hormonal selection pressure. A contemporary mCRPC review states: “The androgen signalling pathway plays a pivotal role in the development of castration resistance” (kulasegaran2024metastaticcastrationresistantprostate pages 3-5). Mechanisms of AR-driven resistance include alterations such as AR pathway amplification/activation and adaptation to low androgen environments (tisseverasinghe2023advancesinparp pages 2-4).

Genomically, mCRPC frequently harbors tumor suppressor and pathway alterations. One review reports “40%–60% of mCRPC cases exhibit aberrations in the AR ... tumour protein p53 and PTEN genes” and that “Approximately 20% of mCRPC patients harbour abnormalities that affect DNA repair genes” (kulasegaran2024metastaticcastrationresistantprostate pages 3-5).

Risk factors (host/demographic; population level)

In the U.S., prostate cancer incidence and mortality show strong demographic disparities that influence metastatic burden. A 2025 CA Cancer J Clin statistics report notes that Black men have double the prostate cancer mortality and 67% higher incidence compared with White men (kratzer2025prostatecancerstatistics pages 1-2).

Note: Specific lifestyle/environmental risk factors (diet, smoking, occupational exposures) were not retrieved in the present corpus and therefore are not summarized here.

Protective factors / gene–environment interactions

Not available from retrieved sources in this run.

3. Phenotypes

Common clinical phenotypes in metastatic disease

Metastatic prostate cancer phenotypes are driven by metastatic site(s) and systemic tumor burden. Key, commonly reported manifestations include: - Bone metastasis–related pain (symptom; QoL impact significant; often drives opioid use and palliative radiotherapy). - Skeletal-related events (SREs) such as pathological fracture, spinal cord compression, need for bone radiation/surgery. - Laboratory marker: rising PSA in many patients, though lineage plasticity can produce low-PSA aggressive variants (not fully quantified in retrieved sources).

The EAU guideline describes SRE endpoints explicitly (pathological fracture, bone radiation/surgery, spinal cord compression) in the denosumab vs zoledronic acid comparison (tilki2024eaueanmestroesurisupsiogguidelineson pages 14-15).

Suggested HPO terms (non-exhaustive; for knowledge base mapping)

Because HPO IDs were not provided in retrieved sources, the following are suggested standard terms (IDs should be verified against HPO): - Bone pain; back pain - Pathologic fracture - Spinal cord compression - Elevated prostate-specific antigen - Anemia (treatment-related, e.g., PARP inhibitor myelosuppression)

Quality of life (QoL)

The mCRPC review emphasizes that treatment goals should include symptom relief and QoL preservation, noting focus on “cancer-related symptoms such as pain” (kulasegaran2024metastaticcastrationresistantprostate pages 1-3).

4. Genetic / Molecular Information

Key genes and pathways (somatic and germline)

Homologous recombination repair (HRR) / DNA damage repair (DDR) alterations are clinically actionable in advanced disease. A 2024 mCRPC review states that “20%–25% [of mCRPC] harbouring somatic or germline alternations in DNA repair genes involved in homologous recombination,” listing common genes “BRCA2, CHEK2, ATM and BRCA1” (kulasegaran2024metastaticcastrationresistantprostate pages 3-5).

A 2023 precision oncology review similarly highlights HRR alterations in metastatic prostate cancer, with frequently altered genes including BRCA2, ATM, CDK12, CHEK2 (gillette2023managementofadvanced pages 5-6).

Pathogenic variants and variant classification

Specific variant-level nomenclature (e.g., BRCA2 c.XXXXdel) and allele frequencies from gnomAD/ClinVar were not available in retrieved sources in this run.

Biomarkers informing therapy

HRR gene alterations → PARP inhibitor combinations

The FDA approval summary specifies that HRRm status in TALAPRO-2 was prospectively determined with a 12-gene NGS panel: “ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, and RAD51C” (heiss2024usfoodand pages 2-4).

MSI-H/dMMR and TMB-H → immune checkpoint blockade eligibility

A large genomic/clinical study defined: - “MSI-H/dMMR prostate cancer was defined as MSIsensor score ≥10 or MSIsensor score ≥3 and <10 with a deleterious MMR alteration” - “TMB-H was defined as ≥10 mutations/megabase” (lenis2024microsatelliteinstabilitytumor pages 1-3).

5. Environmental Information

Not available from retrieved sources in this run.

6. Mechanism / Pathophysiology

Core molecular mechanism chain (high level)

1. Androgen signaling dependence in prostate epithelial tumor cells → response to ADT/AR pathway inhibition.
2. Under treatment pressure, tumors evolve AR pathway reactivation or shift to alternative survival programs, driving castration resistance (kulasegaran2024metastaticcastrationresistantprostate pages 3-5, tisseverasinghe2023advancesinparp pages 2-4).
3. Subsets acquire/harbor DDR/HRR defects; these increase genomic instability and create vulnerabilities to PARP inhibition via synthetic lethality (kulasegaran2024metastaticcastrationresistantprostate pages 3-5, tisseverasinghe2023advancesinparp pages 2-4).
4. A small subset develops MSI-H/dMMR, increasing neoantigen burden and enabling clinically meaningful responses to immune checkpoint blockade (lenis2024microsatelliteinstabilitytumor pages 1-3).
5. Bone metastasis causes osteoclast/osteoblast dysregulation; SRE prevention targets osteoclast signaling (RANKL inhibition) and bone resorption (bisphosphonates) (tilki2024eaueanmestroesurisupsiogguidelineson pages 14-15).

Immune involvement / immunotherapy biomarker data

In a cohort of 2,257 prostate cancer patients with tumor sequencing, prevalence of immunotherapy-relevant genomic subgroups was: - MSI-H/dMMR: 63/2,257 (2.8%) - TMB-H/MSS: 33/2,257 (1.5%) (lenis2024microsatelliteinstabilitytumor pages 1-3)

Among immune checkpoint blockade–treated patients: - MSI-H/dMMR: “45% ... had a RECIST response and 65% had a PSA50 response” - TMB-H/MSS: “No ... had a RECIST response and 50% had a PSA50 response” (lenis2024microsatelliteinstabilitytumor pages 1-3).

Suggested GO biological process terms (examples)

• Androgen receptor signaling pathway
• DNA repair; homologous recombination
• Double-strand break repair
• Osteoclast differentiation; bone remodeling

Suggested Cell Ontology (CL) cell types (examples)

• Prostate epithelial cell / luminal epithelial cell (tumor origin)
• Osteoclast, osteoblast (bone metastasis microenvironment)
• CD8+ T cell (immunotherapy response context)

7. Anatomical Structures Affected

Organ/tissue level

• Primary organ: prostate gland
• Common metastatic sites: bone, lymph nodes; also visceral sites in advanced disease.

Suggested UBERON terms (examples; IDs not provided in retrieved sources)

• prostate gland
• bone tissue (skeletal system)
• lymph node

Subcellular

• Nucleus (AR transcription factor function)
• DNA repair machinery compartments (nuclear)

8. Temporal Development

Typical onset and course

Prostate cancer is predominantly adult/older-adult onset, with metastatic presentation either de novo or after progression from localized disease.

A real-world cohort defined de novo mHSPC operationally as first metastasis within 60 days of first prostate cancer diagnosis (raval2025realworldevidenceof pages 2-4).

Progression

The transition from mHSPC to mCRPC is clinically defined by progression while maintaining castrate testosterone and ongoing ADT; detailed staging frameworks were not extracted from retrieved sources in this run.

9. Inheritance and Population

Epidemiology (recent statistics; U.S.)

A 2025 CA Cancer J Clin report found that overall U.S. prostate cancer incidence trends reversed from “a decline of 6.4% per year during 2007 through 2014 to an increase of 3.0% annually during 2014 through 2021” and that “distant-stage disease has increased by 2.6% annually” in men <55, and by 6.0% (55–69) and 6.2% (≥70) (kratzer2025prostatecancerstatistics pages 1-2).

Racial disparities: Black men have “double the prostate cancer mortality, with 67% higher incidence” vs White men (kratzer2025prostatecancerstatistics pages 1-2). Distant-stage 5-year survival “ranges from 36% in Black men to 43% for AAPI men” (kratzer2025prostatecancerstatistics pages 4-4).

Inheritance

Germline HRR alterations occur in a minority of metastatic patients (e.g., reported germline HRR prevalence ~11.8% in one summarized dataset) (gillette2023managementofadvanced pages 6-7). Specific Mendelian inheritance patterns are not directly applicable to metastatic status (which is a disease stage), but inherited predisposition variants (e.g., BRCA2) increase risk of aggressive disease.

10. Diagnostics

Core clinical tests (metastatic setting)

• PSA monitoring and clinical assessment
• Imaging for staging and response: historically CT/MRI plus bone scan in pivotal trials; PSMA PET/CT increasingly used.

EAU guidance notes that trial evidence defining M1 disease used CT/MRI plus bone scintigraphy and that the impact of newer imaging such as PSMA PET/CT on outcomes has not yet been tested in randomized trials (tilki2024eaueanmestroesurisupsiogguidelineson pages 7-8).

For biochemical recurrence post-prostatectomy, the EAU guideline table recommends: “Perform PSMA PET/CT if the PSA level is >0.2 ng/ml and if the results will influence subsequent treatment decisions” (strength rating weak) (tilki2024eaueanmestroesurisupsiogguidelineson pages 4-5).

Molecular diagnostics / tumor profiling

For mCRPC and advanced disease, molecular testing is used to identify actionable subgroups: - HRR mutations to guide PARP inhibitor use (heiss2024usfoodand pages 2-4, heiss2024usfoodand pages 1-2). - MSI-H/dMMR / TMB-H for pembrolizumab eligibility (lenis2024microsatelliteinstabilitytumor pages 1-3).

11. Outcome / Prognosis

Survival trends at population level

Distant-stage prostate cancer survival has improved over time; the CA Cancer J Clin report indicates distant-stage survival improved “from 55% in the middle 2000s to 66% in 2019–2020” (kratzer2025prostatecancerstatistics pages 4-4).

Prognostic biomarkers (selected)

• HRR status is prognostic and predictive for PARP inhibitor response; BRCA2 alterations are repeatedly associated with higher PARP inhibitor benefit relative to other HRR genes (heiss2024usfoodand pages 1-2, kulasegaran2024metastaticcastrationresistantprostate pages 3-5).
• MSI-H/dMMR predicts response to immune checkpoint blockade; objective responses in ~45% of treated MSI-H/dMMR patients in one cohort (lenis2024microsatelliteinstabilitytumor pages 1-3).

12. Treatment

12.1 First-line systemic therapy for mHSPC (guidelines; real-world implementation)

The EAU 2024 guideline recommends against ADT monotherapy as initial therapy for de novo M1 patients who are eligible for combination therapy and have sufficient life expectancy (strong) (tilki2024eaueanmestroesurisupsiogguidelineson pages 6-7). It strongly recommends ADT combined with AR pathway inhibitor options (abiraterone acetate plus prednisone, apalutamide, or enzalutamide) for fit patients (tilki2024eaueanmestroesurisupsiogguidelineson pages 7-8).

Triplet therapy evidence is incorporated: in the PEACE-1 subgroup, adding abiraterone to ADT+docetaxel improved rPFS (HR 0.50) and OS (HR 0.75) (tilki2024eaueanmestroesurisupsiogguidelineson pages 7-8).

Real-world uptake (US 2017–2023): In a claims-based cohort of 10,717 individuals, ADT+ARPI increased from 13% to 47%, and triplet therapy (ADT+ARPI+docetaxel) increased from 0.8% to 15%, while ADT alone declined from 74% to 36% (raval2025realworldevidenceof pages 1-2).

Guideline recommendation table (visual evidence): EAU 2024 Table 6 summarizes first-line mHSPC recommendations with strength ratings (tilki2024eaueanmestroesurisupsiogguidelineson media 3226c7f4).

12.2 mCRPC standard therapies (selected clinical trial outcomes)

Examples of established systemic therapies and outcomes summarized in a 2024 mCRPC review include: - Docetaxel (TAX-327): median OS 19.2 vs 16.3 months (p < 0.004) (kulasegaran2024metastaticcastrationresistantprostate pages 1-3). - Cabazitaxel (TROPIC): OS 15.1 vs 12.7 months; HR 0.7 (p ≤ 0.0001) (kulasegaran2024metastaticcastrationresistantprostate pages 1-3, kulasegaran2024metastaticcastrationresistantprostate pages 3-5). - Enzalutamide: AFFIRM OS 18.4 vs 13.6 months (HR 0.63); PREVAIL rPFS at 12 months 65% vs 14% (HR 0.19) and OS 32.4 vs 30.2 months (HR 0.7) (kulasegaran2024metastaticcastrationresistantprostate pages 3-5). - Abiraterone: COU-AA-301 OS 14.8 vs 10.9 months (HR 0.65); COU-AA-302 OS 34.7 vs 30.3 months (HR 0.81) (kulasegaran2024metastaticcastrationresistantprostate pages 3-5).

12.3 Biomarker-driven therapy (2023–2024 developments)

HRR-mutated mCRPC: talazoparib + enzalutamide (FDA-approved)

The FDA approval summary states: “The US Food and Drug Administration (FDA) approved talazoparib with enzalutamide for first-line treatment of patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).” (heiss2024usfoodand pages 1-2). Efficacy in the combined HRRm population: rPFS HR 0.45 (95% CI 0.33–0.61; P < .0001); BRCA-mutated subgroup rPFS HR 0.20 (95% CI 0.11–0.36) (heiss2024usfoodand pages 1-2).

Safety is dominated by myelosuppression: decreased hemoglobin any-grade 79%; grade ≥3 anemia 45%; and RBC transfusion in 39% (heiss2024usfoodand pages 6-8).

MSI-H/dMMR metastatic prostate cancer: pembrolizumab (tumor-agnostic)

In a large institutional cohort, MSI-H/dMMR prevalence was 2.8% and responses to ICB were substantial: 45% RECIST response and 65% PSA50 response among treated MSI-H/dMMR patients (lenis2024microsatelliteinstabilitytumor pages 1-3).

12.4 Bone-targeted agents to prevent skeletal-related events (SREs)

EAU guideline evidence summary: - Zoledronic acid (4 mg): fewer SREs vs placebo (33% vs 44%; p = 0.021) (tilki2024eaueanmestroesurisupsiogguidelineson pages 14-15). - Denosumab vs zoledronic acid: longer time to first on-study SRE (20.7 vs 17.1 months; HR 0.82; p = 0.008) (tilki2024eaueanmestroesurisupsiogguidelineson pages 14-15).

Key toxicities include osteonecrosis of the jaw (reported 8.2% in mCRPC) and severe hypocalcemia (8% with denosumab vs 5% with zoledronic acid), motivating dental exam prior to therapy and calcium/vitamin D supplementation (tilki2024eaueanmestroesurisupsiogguidelineson pages 14-15).

Suggested MAXO terms (examples)

• Androgen deprivation therapy
• Androgen receptor pathway inhibitor therapy
• Chemotherapy (taxane)
• Radiotherapy to primary tumor
• PARP inhibitor therapy
• Immune checkpoint inhibitor therapy
• Bisphosphonate therapy
• RANKL inhibitor therapy

13. Prevention

Primary prevention

Not addressed in retrieved sources.

Secondary prevention / screening

Population screening and its association with stage at diagnosis is addressed indirectly via incidence trend analyses. A large multistate cohort found that higher county-level PSA screening prevalence prior to diagnosis was associated with lower odds of advanced stage and lower mortality (kratzer2025prostatecancerstatistics pages 5-6).

Note: Specific USPSTF recommendations were not retrieved in full text in this run.

14. Other Species / Natural Disease

Not available from retrieved sources in this run.

15. Model Organisms

Not available from retrieved sources in this run.

Recent Developments (2023–2024 prioritized) and Real-World Implementations (summary)

Key 2023–2024 developments and implementation signals include: - EAU 2024 guideline updates integrating ARPI intensification and selective triplet therapy in mHSPC (tilki2024eaueanmestroesurisupsiogguidelineson pages 6-7, tilki2024eaueanmestroesurisupsiogguidelineson pages 7-8). - Biomarker-driven first-line mCRPC approval of talazoparib + enzalutamide for HRR gene–mutated disease, with strongest rPFS benefit in BRCA-mutated subgroup (heiss2024usfoodand pages 1-2). - Clarified immunotherapy biomarker performance: MSI-H/dMMR vs TMB-H/MSS distinction, with durable objective responses concentrated in MSI-H/dMMR (lenis2024microsatelliteinstabilitytumor pages 1-3). - Real-world adoption: by 2023, ADT+ARPI (47%) and ADT+ARPI+docetaxel (15%) increased substantially, though 36% still received ADT alone (raval2025realworldevidenceof pages 1-2).

Evidence Map (recent, high-value sources)

Table: This table summarizes major 2024-2025 evidence sources used for metastatic prostate cancer, spanning guidelines, biomarker-driven therapy, epidemiology, and real-world implementation. It highlights key quantitative findings and links them to authoritative publications for rapid reference.

Visual Evidence (Guideline Recommendation Table)

EAU 2024 Table 6 (cropped image) includes first-line mHSPC treatment recommendations with strength ratings (tilki2024eaueanmestroesurisupsiogguidelineson media 3226c7f4).

Limitations / data not captured in this run

• Formal ontology identifiers (MONDO, MeSH IDs) were not retrieved.
• Detailed environmental/lifestyle risk factor meta-analyses were not retrieved.
• Model organism and veterinary disease information were not retrieved.
• PMIDs were not provided in the retrieved text snippets; therefore, PMID fields are left blank unless present in-source.

References

1. (cicchetti2025therapeuticadvancesin pages 1-2): Rossella Cicchetti, Martina Basconi, Giulio Litterio, Angelo Orsini, Marco Mascitti, Alessio Digiacomo, Gaetano Salzano, Octavian Sabin Tătaru, Matteo Ferro, Carlo Giulioni, Angelo Cafarelli, Luigi Schips, and Michele Marchioni. Therapeutic advances in metastatic prostate cancer: a journey from standard of care to new emerging treatment. International Journal of Molecular Sciences, 26:11665, Dec 2025. URL: https://doi.org/10.3390/ijms262311665, doi:10.3390/ijms262311665. This article has 5 citations.

2. (kratzer2025prostatecancerstatistics pages 2-3): Tyler B. Kratzer, Natalia Mazzitelli, Jessica Star, William L. Dahut, Ahmedin Jemal, and Rebecca L. Siegel. Prostate cancer statistics, 2025. CA: A Cancer Journal for Clinicians, 75:485-497, Sep 2025. URL: https://doi.org/10.3322/caac.70028, doi:10.3322/caac.70028. This article has 103 citations and is from a domain leading peer-reviewed journal.

3. (tilki2024eaueanmestroesurisupsiogguidelineson pages 1-3): D Tilki, RCN van den Bergh, and E Briers. Eau-eanm-estro-esur-isup-siog guidelines on prostate cancer. part ii—. Unknown journal, 2024.

4. (kratzer2025prostatecancerstatistics pages 1-2): Tyler B. Kratzer, Natalia Mazzitelli, Jessica Star, William L. Dahut, Ahmedin Jemal, and Rebecca L. Siegel. Prostate cancer statistics, 2025. CA: A Cancer Journal for Clinicians, 75:485-497, Sep 2025. URL: https://doi.org/10.3322/caac.70028, doi:10.3322/caac.70028. This article has 103 citations and is from a domain leading peer-reviewed journal.

5. (raval2025realworldevidenceof pages 1-2): Amit D. Raval, Orsolya Lunacsek, Matthew J. Korn, Natasha Littleton, Niculae Constantinovici, and Daniel J. George. Real-world evidence of combination therapy use in metastatic hormone-sensitive prostate cancer in the united states from 2017 to 2023. JCO Oncology Practice, 21:1174-1184, Feb 2025. URL: https://doi.org/10.1200/op-24-00690, doi:10.1200/op-24-00690. This article has 10 citations and is from a peer-reviewed journal.

6. (kulasegaran2024metastaticcastrationresistantprostate pages 3-5): Tivya Kulasegaran and Niara Oliveira. Metastatic castration-resistant prostate cancer: advances in treatment and symptom management. Current Treatment Options in Oncology, 25:914-931, Jun 2024. URL: https://doi.org/10.1007/s11864-024-01215-2, doi:10.1007/s11864-024-01215-2. This article has 75 citations and is from a peer-reviewed journal.

7. (tisseverasinghe2023advancesinparp pages 2-4): Steven Tisseverasinghe, Boris Bahoric, Maurice Anidjar, Stephan Probst, and Tamim Niazi. Advances in parp inhibitors for prostate cancer. Cancers, 15:1849, Mar 2023. URL: https://doi.org/10.3390/cancers15061849, doi:10.3390/cancers15061849. This article has 29 citations.

8. (tilki2024eaueanmestroesurisupsiogguidelineson pages 14-15): D Tilki, RCN van den Bergh, and E Briers. Eau-eanm-estro-esur-isup-siog guidelines on prostate cancer. part ii—. Unknown journal, 2024.

9. (kulasegaran2024metastaticcastrationresistantprostate pages 1-3): Tivya Kulasegaran and Niara Oliveira. Metastatic castration-resistant prostate cancer: advances in treatment and symptom management. Current Treatment Options in Oncology, 25:914-931, Jun 2024. URL: https://doi.org/10.1007/s11864-024-01215-2, doi:10.1007/s11864-024-01215-2. This article has 75 citations and is from a peer-reviewed journal.

10. (gillette2023managementofadvanced pages 5-6): Claire M. Gillette, Gabriel A. Yette, Scott D. Cramer, and Laura S. Graham. Management of advanced prostate cancer in the precision oncology era. Cancers, 15:2552, Apr 2023. URL: https://doi.org/10.3390/cancers15092552, doi:10.3390/cancers15092552. This article has 20 citations.

11. (heiss2024usfoodand pages 2-4): Brian L. Heiss, Elaine Chang, Xin Gao, Tien Truong, Michael H. Brave, Erik Bloomquist, Ankit Shah, Salaheldin Hamed, Jeffrey Kraft, Haw-Jyh Chiu, Tiffany K. Ricks, Amy Tilley, William F. Pierce, Liuya Tang, Abdelrahmman Abukhdeir, Shyam Kalavar, Reena Philip, Shenghui Tang, Richard Pazdur, Laleh Amiri-Kordestani, Paul G. Kluetz, and Daniel L. Suzman. Us food and drug administration approval summary: talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 42:1851-1860, May 2024. URL: https://doi.org/10.1200/jco.23.02182, doi:10.1200/jco.23.02182. This article has 30 citations and is from a highest quality peer-reviewed journal.

12. (lenis2024microsatelliteinstabilitytumor pages 1-3): Andrew T. Lenis, Vignesh Ravichandran, Samantha Brown, Syed M. Alam, Andrew Katims, Hong Truong, Peter A. Reisz, Samantha Vasselman, Barbara Nweji, Karen A. Autio, Michael J. Morris, Susan F. Slovin, Dana Rathkopf, Daniel Danila, Sungmin Woo, Hebert A. Vargas, Vincent P. Laudone, Behfar Ehdaie, Victor Reuter, Maria Arcila, Michael F. Berger, Agnes Viale, Howard I. Scher, Nikolaus Schultz, Anuradha Gopalan, Mark T.A. Donoghue, Irina Ostrovnaya, Konrad H. Stopsack, David B. Solit, and Wassim Abida. Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:3894-3903, Jul 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3403, doi:10.1158/1078-0432.ccr-23-3403. This article has 62 citations.

13. (raval2025realworldevidenceof pages 2-4): Amit D. Raval, Orsolya Lunacsek, Matthew J. Korn, Natasha Littleton, Niculae Constantinovici, and Daniel J. George. Real-world evidence of combination therapy use in metastatic hormone-sensitive prostate cancer in the united states from 2017 to 2023. JCO Oncology Practice, 21:1174-1184, Feb 2025. URL: https://doi.org/10.1200/op-24-00690, doi:10.1200/op-24-00690. This article has 10 citations and is from a peer-reviewed journal.

14. (kratzer2025prostatecancerstatistics pages 4-4): Tyler B. Kratzer, Natalia Mazzitelli, Jessica Star, William L. Dahut, Ahmedin Jemal, and Rebecca L. Siegel. Prostate cancer statistics, 2025. CA: A Cancer Journal for Clinicians, 75:485-497, Sep 2025. URL: https://doi.org/10.3322/caac.70028, doi:10.3322/caac.70028. This article has 103 citations and is from a domain leading peer-reviewed journal.

15. (gillette2023managementofadvanced pages 6-7): Claire M. Gillette, Gabriel A. Yette, Scott D. Cramer, and Laura S. Graham. Management of advanced prostate cancer in the precision oncology era. Cancers, 15:2552, Apr 2023. URL: https://doi.org/10.3390/cancers15092552, doi:10.3390/cancers15092552. This article has 20 citations.

16. (tilki2024eaueanmestroesurisupsiogguidelineson pages 7-8): D Tilki, RCN van den Bergh, and E Briers. Eau-eanm-estro-esur-isup-siog guidelines on prostate cancer. part ii—. Unknown journal, 2024.

17. (tilki2024eaueanmestroesurisupsiogguidelineson pages 4-5): D Tilki, RCN van den Bergh, and E Briers. Eau-eanm-estro-esur-isup-siog guidelines on prostate cancer. part ii—. Unknown journal, 2024.

18. (heiss2024usfoodand pages 1-2): Brian L. Heiss, Elaine Chang, Xin Gao, Tien Truong, Michael H. Brave, Erik Bloomquist, Ankit Shah, Salaheldin Hamed, Jeffrey Kraft, Haw-Jyh Chiu, Tiffany K. Ricks, Amy Tilley, William F. Pierce, Liuya Tang, Abdelrahmman Abukhdeir, Shyam Kalavar, Reena Philip, Shenghui Tang, Richard Pazdur, Laleh Amiri-Kordestani, Paul G. Kluetz, and Daniel L. Suzman. Us food and drug administration approval summary: talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 42:1851-1860, May 2024. URL: https://doi.org/10.1200/jco.23.02182, doi:10.1200/jco.23.02182. This article has 30 citations and is from a highest quality peer-reviewed journal.

19. (tilki2024eaueanmestroesurisupsiogguidelineson pages 6-7): D Tilki, RCN van den Bergh, and E Briers. Eau-eanm-estro-esur-isup-siog guidelines on prostate cancer. part ii—. Unknown journal, 2024.

20. (tilki2024eaueanmestroesurisupsiogguidelineson media 3226c7f4): D Tilki, RCN van den Bergh, and E Briers. Eau-eanm-estro-esur-isup-siog guidelines on prostate cancer. part ii—. Unknown journal, 2024.

21. (heiss2024usfoodand pages 6-8): Brian L. Heiss, Elaine Chang, Xin Gao, Tien Truong, Michael H. Brave, Erik Bloomquist, Ankit Shah, Salaheldin Hamed, Jeffrey Kraft, Haw-Jyh Chiu, Tiffany K. Ricks, Amy Tilley, William F. Pierce, Liuya Tang, Abdelrahmman Abukhdeir, Shyam Kalavar, Reena Philip, Shenghui Tang, Richard Pazdur, Laleh Amiri-Kordestani, Paul G. Kluetz, and Daniel L. Suzman. Us food and drug administration approval summary: talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 42:1851-1860, May 2024. URL: https://doi.org/10.1200/jco.23.02182, doi:10.1200/jco.23.02182. This article has 30 citations and is from a highest quality peer-reviewed journal.

22. (kratzer2025prostatecancerstatistics pages 5-6): Tyler B. Kratzer, Natalia Mazzitelli, Jessica Star, William L. Dahut, Ahmedin Jemal, and Rebecca L. Siegel. Prostate cancer statistics, 2025. CA: A Cancer Journal for Clinicians, 75:485-497, Sep 2025. URL: https://doi.org/10.3322/caac.70028, doi:10.3322/caac.70028. This article has 103 citations and is from a domain leading peer-reviewed journal.

23. (fizazi2024firstlinetalazoparibwith pages 2-3): Karim Fizazi, Arun A. Azad, Nobuaki Matsubara, Joan Carles, Andre P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C. C. Fong, Eric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G. Healy, Nicola Di Santo, A. Douglas Laird, Fabian Zohren, and Neeraj Agarwal. First-line talazoparib with enzalutamide in hrr-deficient metastatic castration-resistant prostate cancer: the phase 3 talapro-2 trial. Nature Medicine, 30:257-264, Dec 2024. URL: https://doi.org/10.1038/s41591-023-02704-x, doi:10.1038/s41591-023-02704-x. This article has 157 citations and is from a highest quality peer-reviewed journal.

24. (fizazi2024firstlinetalazoparibwith pages 1-2): Karim Fizazi, Arun A. Azad, Nobuaki Matsubara, Joan Carles, Andre P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C. C. Fong, Eric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G. Healy, Nicola Di Santo, A. Douglas Laird, Fabian Zohren, and Neeraj Agarwal. First-line talazoparib with enzalutamide in hrr-deficient metastatic castration-resistant prostate cancer: the phase 3 talapro-2 trial. Nature Medicine, 30:257-264, Dec 2024. URL: https://doi.org/10.1038/s41591-023-02704-x, doi:10.1038/s41591-023-02704-x. This article has 157 citations and is from a highest quality peer-reviewed journal.

25. (lenis2024microsatelliteinstabilitytumor pages 3-5): Andrew T. Lenis, Vignesh Ravichandran, Samantha Brown, Syed M. Alam, Andrew Katims, Hong Truong, Peter A. Reisz, Samantha Vasselman, Barbara Nweji, Karen A. Autio, Michael J. Morris, Susan F. Slovin, Dana Rathkopf, Daniel Danila, Sungmin Woo, Hebert A. Vargas, Vincent P. Laudone, Behfar Ehdaie, Victor Reuter, Maria Arcila, Michael F. Berger, Agnes Viale, Howard I. Scher, Nikolaus Schultz, Anuradha Gopalan, Mark T.A. Donoghue, Irina Ostrovnaya, Konrad H. Stopsack, David B. Solit, and Wassim Abida. Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:3894-3903, Jul 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3403, doi:10.1158/1078-0432.ccr-23-3403. This article has 62 citations.

26. (kratzer2025prostatecancerstatistics pages 3-4): Tyler B. Kratzer, Natalia Mazzitelli, Jessica Star, William L. Dahut, Ahmedin Jemal, and Rebecca L. Siegel. Prostate cancer statistics, 2025. CA: A Cancer Journal for Clinicians, 75:485-497, Sep 2025. URL: https://doi.org/10.3322/caac.70028, doi:10.3322/caac.70028. This article has 103 citations and is from a domain leading peer-reviewed journal.

27. (naqvi2025systemictreatmentoptions pages 1-5): Syed Arsalan Ahmed Naqvi, Muhammad Umair Anjum, Arifa Bibi, Muhammad Ali Khan, Kaneez Zahra Rubab Khakwani, Huan He, Manal Imran, Syeda Zainab Kazmi, Ammad Raina, Ewan K. Cobran, R. Bryan Rumble, Thomas K. Oliver, Neeraj Agarwal, Yousef Zakharia, Mary-Ellen Taplin, Oliver Sartor, Parminder Singh, Jacob J. Orme, Daniel S. Childs, Rahul A. Parikh, Rohan Garje, Mohammad Hassan Murad, Alan H. Bryce, and Irbaz Bin Riaz. Systemic treatment options for metastatic castration resistant prostate cancer: a living systematic review. medRxiv, Apr 2025. URL: https://doi.org/10.1101/2025.04.15.25325837, doi:10.1101/2025.04.15.25325837. This article has 5 citations.

28. (naqvi2025systemictreatmentoptions pages 18-21): Syed Arsalan Ahmed Naqvi, Muhammad Umair Anjum, Arifa Bibi, Muhammad Ali Khan, Kaneez Zahra Rubab Khakwani, Huan He, Manal Imran, Syeda Zainab Kazmi, Ammad Raina, Ewan K. Cobran, R. Bryan Rumble, Thomas K. Oliver, Neeraj Agarwal, Yousef Zakharia, Mary-Ellen Taplin, Oliver Sartor, Parminder Singh, Jacob J. Orme, Daniel S. Childs, Rahul A. Parikh, Rohan Garje, Mohammad Hassan Murad, Alan H. Bryce, and Irbaz Bin Riaz. Systemic treatment options for metastatic castration resistant prostate cancer: a living systematic review. medRxiv, Apr 2025. URL: https://doi.org/10.1101/2025.04.15.25325837, doi:10.1101/2025.04.15.25325837. This article has 5 citations.